BACKGROUND/AIMS: KL-6 mucin is a type of MUC1 mucin. Previous immunohistochemical studies by the authors revealed that, in liver cancer tissues, KL-6 mucin expressed only in intrahepatic cholangiocarcinoma (CC) but not in hepatocellular carcinoma (HCC). The current study performed serological analysis to evaluate KL-6 mucin levels in sera from various liver cancer patients and healthy individuals. METHODOLOGY: Enzyme-linked immunosorbent assay was used to measure KL-6 mucin levels in sera from 8 CC patients, 27 HCC patients, 30 metastatic liver cancer (MC) patients, and 19 healthy individuals. RESULTS: Serum KL-6 mucin levels were significantly higher in CC patients than in healthy individuals (p<0.0001), HCC patients (p<0.0001), and MC patients (p<0.001). Receiver operating characteristic analysis determined the cut-off level of serum KL-6 mucin levels to be 240 U/mL (CC vs. healthy, p<0.001) or 248 U/mL (CC vs. HCC, p<0.001). Using 248 U/mL as a cut-off value, the positive rate for CC patients, healthy individuals, and HCC patients was 100.0%, 15.8%, and 18.5%, respectively. CONCLUSIONS: Elevation of serum KL-6 levels was detectable in CC patients. Thus, KL-6 might be a useful serological marker to distinguish CC patients from HCC patients.
BACKGROUND/AIMS: KL-6 mucin is a type of MUC1 mucin. Previous immunohistochemical studies by the authors revealed that, in liver cancer tissues, KL-6 mucin expressed only in intrahepatic cholangiocarcinoma (CC) but not in hepatocellular carcinoma (HCC). The current study performed serological analysis to evaluate KL-6 mucin levels in sera from various liver cancerpatients and healthy individuals. METHODOLOGY: Enzyme-linked immunosorbent assay was used to measure KL-6 mucin levels in sera from 8 CC patients, 27 HCCpatients, 30 metastatic liver cancer (MC) patients, and 19 healthy individuals. RESULTS: Serum KL-6 mucin levels were significantly higher in CC patients than in healthy individuals (p<0.0001), HCCpatients (p<0.0001), and MC patients (p<0.001). Receiver operating characteristic analysis determined the cut-off level of serum KL-6 mucin levels to be 240 U/mL (CC vs. healthy, p<0.001) or 248 U/mL (CC vs. HCC, p<0.001). Using 248 U/mL as a cut-off value, the positive rate for CC patients, healthy individuals, and HCCpatients was 100.0%, 15.8%, and 18.5%, respectively. CONCLUSIONS: Elevation of serum KL-6 levels was detectable in CC patients. Thus, KL-6 might be a useful serological marker to distinguish CC patients from HCCpatients.
Authors: Jesus M Banales; Jose J G Marin; Angela Lamarca; Pedro M Rodrigues; Shahid A Khan; Lewis R Roberts; Vincenzo Cardinale; Guido Carpino; Jesper B Andersen; Chiara Braconi; Diego F Calvisi; Maria J Perugorria; Luca Fabris; Luke Boulter; Rocio I R Macias; Eugenio Gaudio; Domenico Alvaro; Sergio A Gradilone; Mario Strazzabosco; Marco Marzioni; Cédric Coulouarn; Laura Fouassier; Chiara Raggi; Pietro Invernizzi; Joachim C Mertens; Anja Moncsek; Sumera Rizvi; Julie Heimbach; Bas Groot Koerkamp; Jordi Bruix; Alejandro Forner; John Bridgewater; Juan W Valle; Gregory J Gores Journal: Nat Rev Gastroenterol Hepatol Date: 2020-06-30 Impact factor: 46.802